Compare Fidelity National Information Servcs Inc (FIS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs TransMedics Group Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.04 (market cap $17.71B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Fidelity National Information Servcs Inc is far larger — about 6.5× TransMedics Group Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and TransMedics Group Inc for 24 Days on average.
| FIS | TMDX | |
|---|---|---|
Market Cap | $17.71B | $2.74B |
Volume | 9,047,825 | 949,331 |
Sector | Technology | Health |
52-Week High | $67.94 | $150.42 |
52-Week Low | $32.44 | $61.99 |
Typical Hold Time | 88 Days | 24 Days |
Enterprise Value | $38.22B | $3.13B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 1.54% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth from $10.68B in 2025 to projected $12.2B in 2026 and net income margin expanding to 27.65%. Recent business wins include core banking platform selections and embedded banking launches, positioning FIS for modernization growth. Analyst consensus remains strongly bullish with a $47.15 price target representing 37% upside potential.
FIS presents a compelling value opportunity with attractive valuation multiples (P/E 5.27, P/S 1.46) and strong analyst support, though investors face risks from negative cash flow trends, high debt levels, and technical bearish signals. The company's strategic positioning in banking technology modernization provides growth catalysts, but execution risks and market volatility require careful monitoring.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
